Proteomic approaches in lung cancer biomarker development

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Espert Review of Proteomics

• Publication date

  2009-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1586/14789450.6.1.27PMID 19210125
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gefitinib

  2012cited by this paper
• Gefitinib for the treatment of non-small-cell lung cancer

  2009cited by this paper
• Biomarkers for the lung cancer diagnosis and their advances in proteomics.

  2008cited by this paper
• Mass spectrometry-based proteomics: principles, perspectives, and challenges.

  2008cited by this paper
• Comparison of ELISA and rapid screening tests for the diagnosis of HIV, Hepatitis B and Hepatitis C among healthy blood donors in a tertiary care hospital in Mumbai.

  2008cited by this paper
• Update on screening for lung cancer.

  2008cited by this paper
• Selected reaction monitoring for quantitative proteomics: a tutorial

  2008cited by this paper
• Ultra performance liquid chromatography isotope dilution tandem mass spectrometry for the absolute quantification of proteins and peptides.

  2008cited by this paper
• Mining the plasma proteome for cancer biomarkers

  2008cited by this paper
• Proteomics-driven cancer biomarker discovery: looking to the future.

  2008cited by this paper
• Proteomics analysis in lung cancer: Challenges and opportunities

  2007cited by this paper
• Lung cancer: diagnosis and management.

  2007cited by this paper
• Proteomic Signature Corresponding to the Response to Gefitinib (Iressa, ZD1839), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma

  2007cited by this paper
• Differences in epidemiology, histology, and survival between cigarette smokers and never-smokers who develop non-small cell lung cancer.

  2007cited by this paper
• Biomarkers for lung cancer: clinical uses

  2007cited by this paper
• Quantitative, Multiplexed Assays for Low Abundance Proteins in Plasma by Targeted Mass Spectrometry and Stable Isotope Dilution*S

  2007cited by this paper
• Metabolomic biomarkers: search, discovery and validation

  2007cited by this paper
• 2‐D difference gel electrophoresis of the lung squamous cell carcinoma versus normal sera demonstrates consistent alterations in the levels of ten specific proteins

  2007cited by this paper
• Potentially useful biomarkers for the diagnosis, treatment and prognosis of lung cancer.

  2007cited by this paper
• Lung cancer in never smokers: a review.

  2007cited by this paper
• Identification of putative serum glycoprotein biomarkers for human lung adenocarcinoma by multilectin affinity chromatography and LC‐MS/MS

  2007cited by this paper
• Comparative analysis of various cytohistological techniques in diagnosis of lung diseases

  2007cited by this paper
• Quantitative Mass Spectrometric Multiple Reaction Monitoring Assays for Major Plasma Proteins*

  2006cited by this paper
• Large Scale Protein Profiling by Combination of Protein Fractionation and Multidimensional Protein Identification Technology (MudPIT)*

  2006cited by this paper
• Selective Profiling of Proteins in Lung Cancer Cells from Fine-Needle Aspirates by Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry

  2006cited by this paper
• K-ras mutations in non-small-cell lung carcinoma: a review.

  2006cited by this paper
• Cancer Biomarkers—An Invitation to the Table

  2006cited by this paper
• Cancer Statistics, 2006

  2006cited by this paper
• Tumor markers in detection of lung cancer.

  2006cited by this paper
• Protein biomarker discovery and validation: the long and uncertain path to clinical utility

  2006cited by this paper
• Predictive value of image cytometry for diagnosis of lung cancer in heavy smokers

  2005cited by this paper
• Enzyme immunoassay (EIA)/enzyme-linked immunosorbent assay (ELISA).

  2005cited by this paper
• Expanded screening for HIV in the United States--an analysis of cost-effectiveness.

  2005cited by this paper
• Proteomic profiling of human pleural effusion using two-dimensional nano liquid chromatography tandem mass spectrometry.

  2005cited by this paper
• Differential proteomic serum pattern of low molecular weight proteins expressed by adenocarcinoma lung cancer patients.

  2005cited by this paper
• Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.

  2005cited by this paper
• A streamlined platform for high-content functional proteomics of primary human specimens

  2005cited by this paper
• An Approach to Studying Lung Cancer-related Proteins in Human Blood*S

  2005cited by this paper
• Depletion of multiple high‐abundance proteins improves protein profiling capacities of human serum and plasma

  2005cited by this paper
• Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis

  2005cited by this paper
• Using protein microarray as a diagnostic assay for non-small cell lung cancer.

  2005cited by this paper
• An overview of lung cancer genomics and proteomics.

  2005cited by this paper
• Clinical utility of cytokeratins as tumor markers.

  2004cited by this paper
• Applications of tissue microarray technology in immunohistochemistry: a study on c-kit expression in small cell lung cancer.

  2004cited by this paper
• Prognostic markers

  2004cited by this paper
• Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA).

  2004cited by this paper
• Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: analysis of 1,000 consecutive resections for clinical stage I disease.

  2004cited by this paper
• ProGRP: a new biomarker for small cell lung cancer.

  2004cited by this paper
• Correlation of different markers (p53, EGF-R, c-erbB-2, Ki-67) expression in the diagnostic biopsies and the corresponding resected tumors in non-small cell lung cancer.

  2004cited by this paper
• Protein profiles associated with survival in lung adenocarcinoma

  2003cited by this paper
• Imatinib mesylate in the treatment of chronic myeloid leukaemia

  2003cited by this paper
• Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers.

  2003cited by this paper
• Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer.

  2003cited by this paper
• Early detection of lung cancer: role of biomarkers

  2003cited by this paper
• Tumor Markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in Patients with Non-Small Cell Lung Cancer as an Aid in Histological Diagnosis and Prognosis

  2003cited by this paper
• The Human Plasma Proteome: History, Character, and Diagnostic Prospects

  2003cited by this paper
• A short history of the polymerase chain reaction.

  2003cited by this paper
• HER-2/ neu Protein Expression and Gene Alteration in Stage I-IIIA Non–Small-Cell Lung Cancer: A Study of 140 Cases Using a Combination of High Throughput Tissue Microarray, Immunohistochemistry, and Fluorescent In Situ Hybridization

  2003cited by this paper
• Clinical equivalence of two cytokeratin markers in mon-small cell lung cancer: a study of tissue polypeptide antigen and cytokeratin 19 fragments.

  2003cited by this paper
• Proteomic patterns of tumour subsets in non-small-cell lung cancer.

  2003cited by this paper
• Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.

  2003cited by this paper
• New approaches for biomarker discovery in lung cancer

  2003cited by this paper
• Neuron-specific enolase is an effective tumour marker in non-small cell lung cancer (NSCLC).

  2003cited by this paper
• Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry.

  2003cited by this paper
• Differential expression of carcinoembryonic antigen (CEA) splice variants in whole blood of colon cancer patients and healthy volunteers: implication for the detection of circulating colon cancer cells

  2002cited by this paper
• HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer.

  2002cited by this paper
• The Human Plasma Proteome

  2002cited by this paper
• Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin‐2 receptor α levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma

  2002cited by this paper
• Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients.

  2002cited by this paper
• Differential expression and biodistribution of cytokeratin 18 and desmoplakins in non-small cell lung carcinoma subtypes.

  2002cited by this paper
• c-erbB-2 protein in serum of primary lung cancer patients.

  2002cited by this paper
• Large-scale analysis of the yeast proteome by multidimensional protein identification technology

  2001cited by this paper
• Expression of early lung cancer detection marker: hnRNP-A2/B1 and its relation to microsatellite alteration in non-small cell lung cancer.

  2001cited by this paper
• Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC).

  2001cited by this paper
• Experimental annotation of the human genome using microarray technology

  2001cited by this paper
• Molecular genetic abnormalities in premalignant lung lesions: biological and clinical implications

  2001cited by this paper
• Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer.

  2000cited by this paper
• CYFRA 21-1, TPA-M, TPS, SCC-Ag and CEA in patients with squamous cell lung cancer and in chemical industry workers as a reference group.

  2000cited by this paper
• Proteomic strategies for biomarker identification: progress and challenges.

  2000cited by this paper
• Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer.

  2000cited by this paper
• Isoform Expression of CD44 Adhesion Molecules, Bcl-2, p53 and Ki-67 Proteins in Lung Cancer

  2000cited by this paper
• Proteomic strategies for biomarker identification: progress and challenges.

  2000cited by this paper
• Molecular detection of early lung cancer.

  1999cited by this paper
• p53 mutant immunophenotype and deregulation of p53 transcription pathway (Bcl2, Bax, and Waf1) in precursor bronchial lesions of lung cancer.

  1998cited by this paper
• Use of rituximab, the new FDA-approved antibody.

  1998cited by this paper
• Molecular abnormalities in lung cancer.

  1998cited by this paper
• Systematic functional analysis of the yeast genome.

  1998cited by this paper
• Prognostic markers in resectable non-small cell lung cancer.

  1997cited by this paper
• p53, the Cellular Gatekeeper Review for Growth and Division

  1997cited by this paper
• Revisions in the International System for Staging Lung Cancer.

  1997cited by this paper
• L-Myc overexpression and detection of auto-antibodies against L-Myc in both the serum and pleural effusion from a patient with non-small cell lung cancer.

  1997cited by this paper
• K-ras oncogene activation in atypical alveolar hyperplasias of the human lung.

  1996cited by this paper
• Clinical detection of lung cancer progression markers

  1996cited by this paper
• Lung cancer

  1995cited by this paper
• p53 genetic abnormalities and myc activation in human lung carcinoma

  1994cited by this paper
• Atypical alveolar hyperplasia: Relationship with pulmonary adenocarcinoma, p53, and c‐erbB‐2 expression

  1994cited by this paper
• Carcinoembryonic antigen, cytokeratin expression and mucin composition in hyperplastic and neoplastic polyps of the colorectum.

  1994cited by this paper
• ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis.

  1992cited by this paper
• Clinical significance of ras oncogene activation in human lung cancer.

  1992cited by this paper
• IgM antibody capture ELISA in the diagnosis of Japanese encephalitis, West Nile & dengue virus infections.

  1984cited by this paper

• MicroRNA-mediated modulation of signalling pathways in lung cancer: implications for diagnosis and treatment

  2025cites this paper
• Fluorescent nanomaterials for early detection of cancer biomarkers: a review

  2025cites this paper
• Epigenetic regulation in lung cancer

  2023cites this paper
• Proteomics Principles and Clinical Applications

  2022cites this paper
• Establishment and verification of a prediction model based on clinical characteristics and positron emission tomography/computed tomography (PET/CT) parameters for distinguishing malignant from benign ground-glass nodules.

  2021cites this paper
• Clinical Application of Mass Spectrometry‐Based Proteomics in Lung Cancer Early Diagnosis

  2020cites this paper
• Real-Time Molecular Patterns to support Intraoperative Decision-Making

  2020cites this paper
• The diagnostic performance of lysine(K)-specific demethylase 6B (KDM6B) in non-small cell lung cancer

  2019cites this paper
• High Sensitive Immunoelectrochemical Measurement of Lung Cancer Tumor Marker ProGRP Based on TiO2-Au Nanocomposite

  2019cites this paper
• Développement d'un système autonome de détection et de quantification des microARNs avec une plateforme nanofluidique pour la prise en charge du cancer du pancréas

  2018cites this paper
• Autoantibody-Based Diagnostic Biomarkers: Technological Approaches to Discovery and Validation

  2018cites this paper
• Differential Proteomic Analysis between Small Cell Lung Carcinoma (SCLC) and Pulmonary Carcinoid Tumors Reveals Molecular Signatures for Malignancy in Lung Cancer

  2018cites this paper
• Lung cancer samples preserved in liquid medium: One step beyond cytology

  2017cites this paper
• Recent mass spectrometry-based proteomics for biomarker discovery in lung cancer, COPD, and asthma

  2017cites this paper
• Mass spectrometry imaging for clinical research - latest developments, applications, and current limitations.

  2017cites this paper
• The impact of growth hormone on proteomic profiles: a review of mouse and adult human studies

  2017cites this paper
• Screening and Identification of Molecular Marker for Metastatic Liver Cancer

  2017cites this paper
• Proteomic profiling of human plasma identifies apolipoprotein E as being associated with smoking and a marker for squamous metaplasia of the lung

  2015cites this paper
• Circulating MACC1 as a novel diagnostic and prognostic biomarker for nonsmall cell lung cancer

  2015cites this paper
• ELMO3 is a novel biomarker for diagnosis and prognosis of non-small cell lung cancer.

  2015cites this paper
• Lung Cancer Biomarkers.

  2015cites this paper
• Associations between epidermal growth factor receptor gene mutation and serum tumor markers in advanced lung adenocarcinomas: a retrospective study.

  2014cites this paper
• Serum-based protein biomarkers for detection of lung cancer

  2014cites this paper
• A survey on mining techniques for early lung cancer diagnoses

  2013cites this paper
• STUDYING ABERRANT METHYLATION AND miRNA PROFILING FOR THE DETECTION OF LUNG CANCER BIOMARKERS

  2013cites this paper
• Overexpression of adenylate cyclase-associated protein 1 is associated with metastasis of lung cancer.

  2013influential citation
• Early Diagnosis of Lung Cancer using a Mining Tool

  2013cites this paper
• Biomarkers in Lung Cancer: Integration with Radiogenomics Data

  2013cites this paper
• Digging deeper into the field of the small cell lung cancer tumor marker ProGRP: a method for differentiation of its isoforms.

  2013cites this paper
• Clinical observations on the association between diagnosis of lung cancer and serum tumor markers in combination.

  2013cites this paper
• Analysis of tumor markers in cytological fluid obtained from computed tomography–guided needle aspiration biopsies for the diagnosis of ground‐glass opacity pulmonary lesions

  2013cites this paper
• An omics strategy for discovering pulmonary biomarkers potentially relevant to the evaluation of tobacco products.

  2012cites this paper
• Additional diagnostic value of tumor markers in cytological fluid for diagnosis of non-small-cell lung cancer

  2012cites this paper
• ENHANCING GENE EXPRESSION IN NON SMALL CELL LUNG CANCER CELL LINE NCI H 23 BY 3 D AGGREGATE FORMATION AS EVIDENCED BY PROTEIN PROFILING

  2012cites this paper
• Proteo‐Metabolomic Strategies in the Future of Drug Development

  2012cites this paper
• Molecular biomarkers of lung carcinoma.

  2012influential citation
• Impact of Protein Stability, Cellular Localization, and Abundance on Proteomic Detection of Tumor-Derived Proteins in Plasma

  2011cites this paper
• Analysis of Tumor Markers in the Cytological Fluid Obtained from Computed Tomography-Guided Needle Aspiration Biopsy for the Diagnosis of Non-small Cell Lung Cancer

  2011cites this paper
• Novel glycan biomarkers for the detection of lung cancer.

  2011cites this paper
• Urinary metabonomic study of lung cancer by a fully automatic hyphenated hydrophilic interaction/RPLC-MS system.

  2010cites this paper
• Have advanced research technologies made real impact on respiratory medicine?

  2010cites this paper